Solstice, an AI-native marketing agency focused on accelerating pharma commercialization, announced it has raised $21 million in Series A funding led by Transformation Capital with participation from Twelve Below, Virtue Ventures, and others. The funding round brings the company’s total funding to approximately $25 million.
The new capital will support go-to-market expansion, product development, and team growth across product and customer-facing functions.
Solstice is focused on helping life sciences companies accelerate the commercialization of new drugs and medical products. The company said pharmaceutical commercialization remains heavily burdened by lengthy medical, legal, and regulatory (MLR) review cycles, with even routine marketing assets often taking months to gain approval.
The company’s platform ingests clinical data, FDA documents, and approved literature to generate compliant marketing campaigns, digital ads, and communications for healthcare providers and patients. Solstice combines proprietary pharmaceutical marketing AI models with in-house subject matter experts to review and optimize content before it reaches regulatory teams.
According to the company, customers are able to launch campaigns 12 times faster than through traditional agencies, with content moving from concept to MLR submission in under 48 hours and becoming market-ready in roughly 10 days. Solstice also said customers are producing nearly three times more content per quarter while reducing average MLR review rounds from 3.2 to 1.2.
The company added that it now serves more than a dozen pharmaceutical companies, including several top 20 pharmaceutical brands across oncology, immunology, and metabolic diseases.
KEY QUOTES:
“We built Solstice to help life sciences teams bring therapeutics to market faster by unifying content creation, medical review and performance insights in a single AI-native system that generates beautiful content, grounds every claim in clinical evidence before MLR review and measures what content will actually move the needle in driving physician and patient action. Our customers used to run three review cycles per asset; now they run one or two at most, and content that used to take months goes out in 10 days. Most importantly, they create more personalized, higher-performing content that helps them compete in increasingly crowded biopharma markets.”
Aris Saxena, Co-Founder And CEO, Solstice
“Before Solstice, getting a single marketing asset through MLR could take weeks of back-and-forth that delayed launch and healthcare provider outreach. Now we move from draft to approved in days, which means our team can actually deliver on the personalization and pace a modern brand demands.”
Kristine Saffrin, Marketing Director, Alexion Pharmaceuticals
“Bringing a new drug to market is one of the most valuable and heavily regulated processes in healthcare, yet the commercialization workflow has barely changed in decades. Solstice is using AI to fix that — helping pharma brands move faster without compromising compliance. Customers are already seeing real results via faster reviews and meaningful cost savings. We’re thrilled to lead this round and partner with the Solstice team.”
Vinay Shah, Partner And Founding Team Member, Transformation Capital
